A Phase I Dose-escalation Study, Randomized Comparison with Active Control to Evaluate the Safety and Pharmacokinetics of a Single Administration of ND-340 Via Adductor Canal Block (ACB) and IPACK Block in Healthy Volunteers

Nang Kuang Pharmaceutical Co., Ltd.1 个研究点分布在 1 个国家目标入组 24 人开始时间: 2022年7月8日最近更新: 2024年11月27日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Nang Kuang Pharmaceutical Co., Ltd.
入组人数: 24
试验地点: 1
主要终点: Changes in physical examination

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This study focuses on ND-340 extended release injection suspension for healthy volunteers with a one-time nerve blockade to determine the safety, tolerability, and pharmacokinetic profile.

详细描述

The current investigational product, ND-340, is a bupivacaine microsphere injection with an extended release profiling. Lipid microsphere, or liposphere, has been proposed as new type of lipid-based encapsulation system for drug delivery of bioactive compounds especially lipophilic compound.

ND-340 has not been studied in human before. However, MARCAINE® and EXPAREL® are both FDA-approved drugs, which contain the same active pharmaceutical ingredient (API) as ND-340, which is bupivacaine. MARCAINE® is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.

In this study, Investigators will focus on determining the safety, tolerability, and pharmacokinetic profile of ND-340.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 20 Years 至 45 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•20 - 45 year-old healthy male subjects or female subjects who are in non-lactating and non-pregnant status.
•Subjects must have a Body Mass Index (BMI) of 18.5 to 30.0 Kg/m², inclusive. For male subjects, body weight must be above 50 kg; for female subjects, body weight must be above 45 kg. BMI = Weight (kg)/Height (m2).
•Female subject with childbearing potential must have a negative serum pregnancy test at the screening visit.
•Able and willing to comply with all study visits and procedures.
•The informed consent form has been read, signed and dated by the subject.
•Able to communicate well with the investigator, comply with study questionnaires, and other instruments used for collecting subject-reported outcomes.

排除标准

•Subject has a sitting pulse rate outside the reference range of 50 to 90 beats per minute or an ear temperature outside the reference range of 35.0 to 37.5°C or a sitting blood pressure less than 90/50 mmHg or more than 140/90 mmHg at screening visit.
•Subject has clinically significant results of physical examination, laboratory tests, electrocardiogram, or chest X-ray as judged by the investigator at the screening visit.
•With abnormal results of sensory and neurological assessment as judged by the investigator at the screening visit.
•Presence of liver disease or liver injury as indicated by an abnormal liver function profile such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkalinephosphatase (ALP), or total bilirubin, if any one of them is out of the reference range.
•Presence of impaired renal function as indicated by abnormal creatinine or blood urea nitrogen values or abnormal urinary constituents, if any one of them is out of the reference range.
•Known of active infection with HIV, HBV, or HCV as defined by blood tests at the screening visit.
•Presence of clinically significant illness, such as cardiovascular disease, cerebrovascular disease, metabolic disease, respiratory disease, neurological disease, psychiatric disease, cancers or immunological disease, may increase the risk of study as judged by the investigator at the screening visit.
•Subject does not agree not to take any prescription, over-the-counter medication, herbal medicine and dietary supplement (including multivitamins) within two weeks before hospital admission and until the end of the study.
•Subject does not agree not to consume any beverage or food that might affect the drug metabolism, such as pomelo, grapefruit or related products within one week before hospital admission and until the end of the study.
•Subject does not agree not to consume any caffeine-containing product (e.g., tea, coffee, coke, or chocolate) 3 days prior to hospital admission and until the end of the study.
•Subject does not agree not to consume any product containing tobacco, nicotine (such as e-cigarettes, nicotine gum), and alcohol 3 days prior to hospital admission and until the end of the study.
•Administration of an investigational drug within 2 months or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration; or planned administration of another investigational product or procedure during the study period.
•Donation or loss of more than 500 mL and 250 mL of blood within 3 months and 2 months before the screening visit, respectively.
•Known with a history of allergy or hypersensitivity to medicine as judged by the investigator at the screening visit.
•Female subject who is breast-feeding, pregnant, or planning to become pregnant.
•Subject does not agree to use effective non-hormonal contraception method to prevent from pregnancy ('double barrier method': condoms used concomitantly with vaginal sponge, diaphragm or intra-uterine contraceptive device) or abstain from sexual behavior with his/her partner from screening until the end of the study.
•Individual is not eligible to be a subject for other reasons based on the judgment of investigator.

研究组 & 干预措施

Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection

Active Comparator

Marcaine® at 150 mg in each cohort.

干预措施: Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection (Drug)

ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension

Experimental

ND-340(90-320 mg) at dose escalations

干预措施: ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension (Drug)

结局指标

主要结局

Changes in physical examination

时间窗: Screening visit, day -1, Day 6

To definition safety profile including general appearance, HEENT, neck, Lymph nodes, skin, cardiovascular, pulmonary, abdomen, neurological system, musculoskeletal/joints

The tolerability and maximal tolerated dose (MTD) of ND-340 by dose-limiting toxicities (DLTs)

时间窗: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 18, 24, 32, 44, 56, 68, 80, 92,104,116,128,140 hour

The incidence of DLT will be summarized by each cohort. The number of subject who has DLT will be summarized by cohorts. and the determination of MTD in this study will be provided.

Cmax